Prefer to listen? Here's the narrated briefing on this area.
Listen to Healthcare and medicine
Plus unlocks audio streaming. Pro adds downloadable audio, video, certificates, and more.
Evidence & Reach
DeepMind's AlphaFold predicted the structure of every known protein and earned its creators the 2024 Nobel Prize in Chemistry — research that previously took years per protein now takes minutes. The FDA has cleared 700+ AI-enabled medical devices, primarily in radiology and cardiology imaging where AI consistently matches or exceeds specialist accuracy for early-stage cancer detection. AI-powered clinical scribes (Abridge, Nuance DAX, Suki) are returning roughly two hours per day to primary-care physicians by handling documentation in real time. In 2026 the systemic layer caught up: the US Medicare ACCESS program opened the first federal payment lane for AI care agents — a reimbursement milestone that moves clinical AI from pilot toward standard-of-care economics — and a peer-reviewed Science study found OpenAI's o1 model out-diagnosed two attending physicians on emergency-room triage cases.
Sources:AlphaFold (DeepMind / Nobel Prize 2024)FDA AI/ML-enabled devices listNEJM AI Clinical StudiesMedicare's AI-built payment model (TechCrunch, 2026)First AI-designed vaccine enters trials (ITV, 2026)
A Specific Story
A primary-care physician at Kaiser Permanente, using Abridge during patient visits, finishes notes by 5:30pm instead of taking them home at 9pm. Multiply that by 70,000 US primary-care physicians and you have a real answer to the physician-burnout crisis — and patients getting more eye contact during their appointments, less typing.
What's Next
The next wave: AI-designed antibiotics (the first novel structural class in 60 years, identified by MIT researchers using machine learning, is heading toward clinical trials), AI-augmented surgical robotics with sub-millimeter precision, and predictive risk models that flag deterioration in ICU patients hours before traditional vital-signs alarms. AI has also begun designing therapeutics outright rather than only analyzing them — the University of Cambridge started human trials of the first vaccine whose core component was designed entirely by AI, and in one striking case GPT-5 cracked a three-year immunology puzzle from an unpublished lab dataset.
Recent Top AI Stories showing progress in this area.
Google researchers estimate body fat and metabolic risk from an ordinary phone photo
Google's PhotoScan model estimates body composition — including the visceral fat ratios that a scale and a tape measure cannot see — from standard two-dimensional smartphone pictures. It was pre-trained on more than 35,000 UK Biobank participants with clinical scan ground truth, fine-tuned on 677 adults photographed with real phones, and validated against a 132-person longitudinal trial. It beat smartwatch bioimpedance on body fat percentage and improved insulin-resistance classification well past demographics alone. Google calls it a research prototype, not a product.
Google's AMIE matches primary care doctors in a video consultation trial
Google Research reported that AMIE (Video), a version of its medical dialogue system that handles live audio and video, was rated on par with board-certified primary care physicians on history-taking, diagnostic accuracy, management and communication. The randomized study covered 100 clinical scenarios and 300 consultations with trained patient actors, scored by 20 independent physicians. AMIE rated significantly higher than the doctors at eliciting physical signs and guiding examinations. It remains research-only — every consultation used actors, not real patients.
Israel's Sheba becomes OpenAI's first hospital deployment outside the United States
Sheba Medical Center in Ramat Gan is rolling out ChatGPT for Healthcare to physicians, nurses, researchers and administrative staff across its network — the first international deployment of OpenAI's hospital platform. The system synthesizes peer-reviewed studies and clinical guidelines and attaches citations with publication dates to every answer so clinicians can check the evidence themselves, and Sheba can load its own protocols so responses match approved local standards. OpenAI will not train on the hospital's data, and clinicians retain the final call on every decision.
AI-designed enzymes outperform nature's gene-editing proteins in a new Science study
Researchers used an AI protein-design model to invent synthetic versions of a compact gene-editing enzyme — a small cousin of the CRISPR proteins — and the best designs beat the natural reference. In human cells, two AI-designed variants hit 46 and 50 percent editing efficiency versus 28 percent for the original, with nearly fourfold gains at some targets. Published in the journal *Science*, the work shows generative models can expand the gene-editing toolbox with smaller, more effective enzymes — a boost for future gene therapies where delivery space is tight.
Google DeepMind sets out a bioresilience plan for pandemic defense
Google DeepMind and Isomorphic Labs laid out how they intend to handle biology — restricting misuse of their models while opening them to governments and scientists working on biosecurity. The two describe more than 15 partnerships with government bodies, biosecurity organizations, and research groups, and point to work already running: AlphaFold and AlphaGenome for pathogen characterization, AlphaEvolve tuned for metagenomic sequencing to catch outbreaks earlier, and a unit inside Isomorphic aimed at designing countermeasures quickly when a novel pathogen appears. Extending SynthID-style watermarking to screen DNA synthesis orders comes next.